<VariationArchive VariationID="2427196" VariationName="NC_000011.9:g.(?_64577559)_(64578852_?)del" VariationType="Deletion" Accession="VCV002427196" Version="3" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-17" DateCreated="2023-02-13" MostRecentSubmission="2024-06-09">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1949968" VariationID="2427196">
      <GeneList>
        <Gene Symbol="MEN1" FullName="menin 1" GeneID="4221" HGNC_ID="HGNC:7010" Source="submitted" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>11q13.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="64803516" stop="64811294" display_start="64803516" display_stop="64811294" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" start="64570985" stop="64578765" display_start="64570985" display_stop="64578765" Strand="-" />
          </Location>
          <OMIM>613733</OMIM>
          <Haploinsufficiency last_evaluated="2022-01-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=MEN1">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2022-01-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=MEN1">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NC_000011.9:g.(?_64577559)_(64578852_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>11q13.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" innerStart="64577559" innerStop="64578852" display_start="64577559" display_stop="64578852" variantLength="1294" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000011.9" sequenceAccession="NC_000011" sequenceVersion="9" change="g.(?_64577559)_(64578852_?)del" Assembly="GRCh37">
            <Expression>NC_000011.9:g.(?_64577559)_(64578852_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000011.9:g.(?_64577559)_(64578852_?)del AND Multiple endocrine neoplasia, type 1" Accession="RCV003123030" Version="3">
        <ClassifiedConditionList TraitSetID="5472">
          <ClassifiedCondition DB="MedGen" ID="C0025267">Multiple endocrine neoplasia, type 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2020-12-02" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2020-12-02" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2023-02-13" MostRecentSubmission="2024-06-09">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">12112656</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15082967</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">17853334</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">19174080</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29036195</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="5472" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="12656" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">MEA I</ElementValue>
                <XRef Type="MIM" ID="131100" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Endocrine adenomatosis multiple</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MEN 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Wermer syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Multiple endocrine neoplasia, type 1</ElementValue>
                <XRef ID="Multiple+endocrine+neoplasia+type+1/4955" DB="Genetic Alliance" />
                <XRef ID="30664006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">MEN I</ElementValue>
                <XRef Type="MIM" ID="131100" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MEN1</ElementValue>
                <XRef Type="MIM" ID="131100" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Multiple endocrine neoplasia type 1 (MEN1) includes varying combinations of more than 20 endocrine and non-endocrine tumors. Endocrine tumors become evident either by overproduction of hormones by the tumor or by growth of the tumor itself. Parathyroid tumors are the most common MEN1-associated endocrinopathy; onset in 90% of individuals is between ages 20 and 25 years with hypercalcemia evident by age 50 years; hypercalcemia causes lethargy, depression, confusion, anorexia, constipation, nausea, vomiting, diuresis, dehydration, hypercalciuria, kidney stones, increased bone resorption/fracture risk, hypertension, and shortened QT interval. Pituitary tumors include prolactinoma (the most common), which manifests as oligomenorrhea/amenorrhea and galactorrhea in females and sexual dysfunction in males. Well-differentiated endocrine tumors of the gastro-entero-pancreatic (GEP) tract can manifest as Zollinger-Ellison syndrome (gastrinoma); hypoglycemia (insulinoma); hyperglycemia, anorexia, glossitis, anemia, diarrhea, venous thrombosis, and skin rash (glucagonoma); and watery diarrhea, hypokalemia, and achlorhydria syndrome (vasoactive intestinal peptide [VIP]-secreting tumor). Carcinoid tumors are non-hormone-secreting and can manifest as a large mass after age 50 years. Adrenocortical tumors can be associated with primary hypercortisolism or hyperaldosteronism. Non-endocrine tumors include facial angiofibromas, collagenomas, lipomas, meningiomas, ependymomas, and leiomyomas.</Attribute>
                <XRef ID="NBK1538" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3829" />
                <XRef ID="3829" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301710</ID>
                <ID Source="BookShelf">NBK1538</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2010">
                <ID Source="PubMed">20065170</ID>
              </Citation>
              <Citation Type="general" Abbrev="Brandi et al., 2001">
                <ID Source="PubMed">11739416</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="general" Abbrev="Thakker et al., 2012">
                <ID Source="PubMed">22723327</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Endocrine and Neuroendocrine Neoplasia genetics">
                <ID Source="PubMed">26389271</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2015">
                <ID Source="PubMed">26324357</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesÂ®), Neuroendocrine and Adrenal Tumors, 2023</CitationText>
              </Citation>
              <XRef ID="652" DB="Orphanet" />
              <XRef ID="C0025267" DB="MedGen" />
              <XRef ID="D018761" DB="MeSH" />
              <XRef ID="MONDO:0007540" DB="MONDO" />
              <XRef Type="MIM" ID="131100" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="7076190" SubmissionDate="2024-06-04" DateLastUpdated="2024-06-09" DateCreated="2023-02-13">
        <ClinVarSubmissionID localKey="NM_130799.2_11_Partial deletion (exons 1-2)_64577558_64578852|MedGen:C0025267" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003796260" DateUpdated="2024-06-09" DateCreated="2023-02-13" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-12-02">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">15082967</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29036195</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">19174080</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12112656</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">17853334</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. Similar deletions including the initiator codon have been observed in individual(s) with clinical features of MEN1-related conditions (PMID: 15082967, 29036195, 19174080). This variant results in the deletion of exon 1 and part of exon 2 (c.-774_23del) of the MEN1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MEN1 are known to be pathogenic (PMID: 12112656, 17853334).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="MEN1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000011.9:g.(?_64577559)_(64578852_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0025267" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12699154</SubmissionName>
          <SubmissionName>SUB14505679</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="7076190" TraitType="Disease" MappingType="XRef" MappingValue="C0025267" MappingRef="MedGen">
        <MedGen CUI="C0025267" Name="Multiple endocrine neoplasia, type 1" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

